UHS: The De Novo Math Gets Harder Just as the Medicaid Cliff Comes Into View
A low-end reiteration, pushed-out hospital break-evens and a $175–200 million 2027 supplemental-payment headwind overshadow another quarter of buybacks at a 5x multiple.
UHS · Earnings Call · 2026-10-28
A low-end reiteration with a different quality
UHS came into this print with the tape already improving: the stock is up 18.1% over the last 90 trading days. But it is still 29.5% below its November 2025 peak and 8.5% below its recent high, so the market has been bidding the cheapness, not the operating momentum. The Q3 call explains why. Adjusted EPS was $5.22, down 8% year over year, and adjusted EBITDA less NCI was $625 million versus $671 million. Management found $12 million of net favorable items — $47 million of supplemental Medicaid benefits, $26 million of added professional and general liability reserves tied largely to a Cumberland litigation settlement, and $8.5 million of Talkspace transaction costs — but the underlying quarter still missed internal expectations. “Excluding these items, adjusted EBITDA less NCI was below our internal expectations despite modest sequential improvement. The shortfall primarily reflected a slower than expected ramp-up at our de novo hospitals and softer than expected surgical trends.” — Steve Filton, Chief Financial Officer · 2026-10-28 That is the key distinction: this was not a clean beat masked by conservatism. It was a low-end reiteration of 2026 guidance, with execution slippage now visible enough to matter. At roughly 5x trailing net income, the valuation already assumes a lot of bad news. The question is whether the bad news is fully identified.The de novo and certification overhang is getting longer
The freshest company-specific signal is timing. Laurel Ridge is now the top-curated keyword for UHS this quarter, and not because the San Antonio behavioral facility is suddenly a growth engine. The hospital is still working toward recertification, which management expects during 2027, and is losing roughly $5 million to $10 million per quarter while it operates without certification. Before losing certification, it generated $20 million to $25 million of pre-tax income. Palm Beach Gardens opened into the South Florida summer — a difficult season — and lost about $15 million in the quarter, though management says volumes are improving monthly and should benefit as Florida’s busy winter season arrives. Cedar Hill in Washington, D.C. remains the bigger drag at roughly $10 million a month, and the break-even date has slipped. “...we now expect the hospital to reach operational break even in the first half of 2027, compared with our prior expectations of the fourth quarter of 2026.” — Steve Filton, Chief Financial Officer · 2026-10-28 That is a meaningful change from the July call, when the message was more confident:The combined 2026 operating losses from these facilities are expected to be $80 million to $100 million, and management argues a meaningful portion can be recovered in 2027. That is plausible, but it is now a show-me recovery rather than a base-case assumption.We are expecting Cedar Hill to, be at breakeven this year.
The surgical mix problem is old, but it has teeth now
Acute care volumes looked strong — same-facility adjusted admissions rose 4.9% and emergency department visits rose 4.6% — but same-facility surgeries fell 0.7%, and revenue per adjusted admission declined 1.7%. Management estimates the medical-versus-surgical mix pressure alone reduced pricing growth by about 100 basis points, leaving underlying rate growth around 3%, at the low end of its stated range. The explanation is familiar: procedures are migrating to ambulatory surgery centers and physician offices, with GI and orthopedics called out. What is new is the candor about how that migration is feeding back into hospital operations, including difficulty covering GI call in emergency rooms. “...the trend towards a slightly weaker surgical mix is an acceleration of existing trends that we have seen for some time.” — Steve Filton, Chief Financial Officer · 2026-10-28 This is not a one-quarter anomaly, and the prior call already flagged the same shift: “I think we are seeing... continued shift of certain elective and outpatient procedures... into alternate site settings, ASCs, freestanding imaging, etc.” — Steve G. Filton, Chief Financial Officer · 2026-07-28 The relevant keyword cluster — procedural volumes, med surg mix, and the declining surgical volumes theme — is therefore less a fresh shock than a slow-burning margin headwind that is now harder to ignore.2027: the first hard number on the Medicaid cliff
The most important new information on the call was not in the quarter. It was the 2027 bridge. Management quantified a $175 million to $200 million Medicaid supplemental-payment headwind for 2027, driven mainly by prior-year amounts recorded in 2026 for programs in Florida, Nevada, Ohio, California and Washington, D.C., plus the initial provider-tax impact from OB-3 funding cuts.That is large against a quarterly adjusted EBITDA base of $625 million. Add roughly $15 million from annualizing the second-half exchange run rate, and the policy math gets uncomfortable. Medicaid work requirements are harder to size because state guidance on medical-frailty exemptions is still open, but management gave the exposure: Medicaid volumes in expansion states represent about 15% of acute care adjusted admissions and 30% of behavioral health patient days. The market has known about OB-3 for quarters; what changed here is specificity and timing. The growth algorithm still works on paper, but it now has to absorb a visible 2027 air pocket.As it relates to Medicaid supplemental payments, we estimate the 2027 headwind will be approximately $175 million-$200 million.